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Grippotyphosa, and Pomona and where 
serogroup Icterohaemorraghiae is not 
detectable (2). These findings contrast 
with human leptospirosis findings from 
La Réunion and the Seychelles, where 
the Icterohaemorraghiae serogroup is 
most common (3).
Our MAT-derived data cannot 
discriminate between recent and past 
Leptospira infections, nor can these 
data be used to determine the severity 
of the disease in the Union of the Co-
moros. Nonetheless, the data strongly 
support the presence of human lepto-
spirosis on the 3 islands of the Union 
of the Comoros and emphasize the 
need for a proper diagnosis to ascer-
tain the number of leptospirosis cases 
among the acute febrile illnesses in 
this country.
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To the Editor: Cryptococcal 
meningitis is the second leading cause 
of AIDS-related deaths in Africa. The 
prolonged hospitalization necessary 
for optimal management may predis-
pose severely immunocompromised 
persons to hospital-acquired infec-
tions. Limited data are available for 
sub-Saharan Africa regarding mul-
tidrug-resistant infections (1,2). We 
hypothesized that bacteremia was a 
major cause of death.
We reviewed bacteremia episodes 
in cryptococcal meningitis cohorts in 
Kampala, Uganda (n = 115 episodes) 
and Cape Town, South Africa (n = 
72) during November 2010–April 
2013. Data were obtained from the 
prospective cryptococcal optimal an-
tiretroviral therapy timing trial (www.
clinicaltrials.gov:NCT01075152), a 
randomized strategy trial assessing op-
timal antiretroviral therapy timing (n = 
142) and another prospective observa-
tional cohort in Cape Town (n = 45).
We enrolled HIV-infected adults 
who had a first episode of cryptococcal 
meningitis diagnosed by cerebrospinal 
fluid  culture or cryptococcal antigen 
testing. Standardized treatment was in 
accordance with World Health Organi-
zation (WHO) guidelines: amphoteri-
cin deoxycholate, 0.7–1.0 mg/kg/d for 
14 days, and fluconazole, 800 mg/d, 
requiring a minimum 14-day hospi-
talization (3). Each person provided 
written informed consent. Institutional 
review board approval was obtained.
Blood cultures were obtained in 
accordance with physician discre-
tion, typically with new onset fever 
(>38°C) unrelated to amphotericin. 
Two aerobic blood cultures were ob-
tained from 1 peripheral site and not 
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from central catheters. BACTEC 
(Becton Dickinson, Franklin Lakes, 
NJ, USA) or BacT/ALERT (Bio-
Mérieux, Durham, NC, USA) bottles 
were incubated at 37°C in automated 
instruments for 5 days. Drugs were 
given empirically at physician discre-
tion and adjusted after culture/suscep-
tibility results were obtained.
Each bacteremic episode was 
classified as a true pathogen, contami-
nant, or indeterminate on the basis of 
clinical scenario and bacterial isolates. 
Data extraction from case report forms 
elicited demographics, microbiology 
results, antimicrobial drug therapy, 
and clinical outcomes. We determined 
risk factors between cases and con-
trols who had cryptococcal meningitis 
without bacteremia/sepsis.
Descriptive statistical analysis re-
ported median and interquartile range 
(IQR). Risk was expressed as odds 
ratio with 95% CIs calculated by lo-
gistic regression. Significance was de-
fined as p<0.05 by Fischer exact test 
(SPSS 21; IBM, Armonk, NY, USA). 
Variables with p<0.10 by univariate 
analysis were entered in a multivari-
able model.
We evaluated 187 persons with 
cryptococcal meningitis who had a 
median CD4 count of 27 cells/μL (IQR 
9–76). Forty-three blood cultures were 
prepared for 40 patients with febrile 
episode(s), of which 37 were posi-
tive. Median time from admission to 
suspected bacteremia was 14 days 
(IQR 9–17 days). All episodes were 
detected >72 h after admission and 
classified as nosocomial bacteremia. 
Seven isolates were considered con-
taminants because clinical improve-
ment occurred without appropriate 
therapy. Thus, 30 cultures for 28 per-
sons (cohort incidence 15%) were 
classified as true bacteremia with 
compatible clinical syndrome. Twen-
ty-three bacteremic episodes occurred 
in Kampala (incidence 18%). Seven 
episodes occurred in 5 patients in 
Cape Town (incidence 7%).
The most frequent microbiologic 
etiologies were Klebsiella pneumoni-
ae (9 episodes), Staphylococcus au-
reus (8), and Pseudomonas spp. (3) 
(Table). Methicillin-resistant S. aureus 
constituted 6 of 8 S. aureus isolates.
Ceftriaxone was the most com-
mon empiric drug used, for which 23 
(77%) of 30 isolates were resistant. 
Eleven (46%) of 24 isolates were 
resistant to ciprofloxacin. Among 
bacteremic patients, 12 (43%) of 28 
died within 30 days after hospital-
ization. The 30-day mortality rate 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	20,	No.	4,	April	2014	 723
Table.	Characteristics	of		28	patients		with	cryptococcal	meningitis,	Uganda	and	South	Africa,	November	2010–April	2013* 
Patient Blood	culture	isolate Hospital 30-d	outcome 
Ceftriaxone	
susceptibility† 
Fluoroquinolone	
susceptibility† 
1 Staphylococcus aureus (MRSA) K Died R NT 
2 S. aureus (MRSA) K Survived R NT 
3 S.. aureus (MRSA) C Survived R S 
4 S. aureus (MRSA) C Survived R R 
5 S. aureus (MRSA) C Died R S 
6 S. aureus (MSSA) K Survived S NT 
7 S. aureus (MSSA) K Survived S NT 
8‡ S. aureus (MRSA) C Survived R R 
8 Enterobacter cloacae C Survived R S 
9 Klebsiella pneumoniae K Survived R R 
10 K. pneumoniae K Died R R 
11 K. pneumoniae K Survived S S 
12 K. pneumoniae K Died R S 
13 K. pneumoniae K Died R R 
14 K. pneumoniae K Died R R 
15 K. pneumoniae K Survived R R 
16 K. pneumoniae C Survived R NT 
17 K. pneumoniae C Died R S 
18 Pseudomonas putida K Died S S 
19 Pseudomonas aeruginosa K Survived R R 
20 Pseudomonas spp. K Died R NT 
21 Salmonella spp. K Survived S S 
22 Salmonella spp. K Died S S 
23 Burkholderia cepacia K Survived R NT 
24 B. cepacia K Survived S S 
25 Citrobacter freundii K Died R S 
26 Acinetobacter baumanii K Survived R S 
27 Enterobacter spp. K Died R R 
28‡ Enterobacter cloacae C Survived R S 
28 Stenotrophomonas maltophilia C Survived R R 
*Sixteen	(57%)	of	28	patients	survived;		7	(23%)	of	30	isolates	were	susceptible	to	ceftriaxone,	and	13	(54%)	of 24	isolates	were	susceptible	to	
fluoroquinolone.	MSRA,	methicillin-resistant S aureus;	K,	Kampala,	Uganda;	R,	resistant;	NT,	not	tested;	C,	Cape	Town,	South	Africa;	S,	sensitive;	
MSSA,	methicillin-sensitive	S. aureus. 
†Drug sensitivity	testing	performed	by	using	the	Kirby-Bauer	method	in	Cape	Town,	South	Africa,	and	a	Phoenix	Automated	Microbiology	System	
(Becton,	Dickinson,	Franklin	Lakes,	NJ,	USA)	in	Kampala,	Uganda. 
‡Two	patients	each	had	2	episodes	of	bacteremia. 
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for persons with cryptococcal men-
ingitis but without bacteremia was 
30% (47/158); 1 patient was lost to 
follow-up. Thus, the estimated at-
tributable mortality rate for bactere-
mia was 13% (odds ratio 1.8, 95% CI 
0.78–4.0, p = 0.17) compared with 
patients without bacteremia during 
their initial hospitalization.
Case–control comparisons iden-
tified no risk factors for bacteremia 
(online Technical Appendix, wwwnc.
cdc.gov/EID/article/20/4/13-1277-
Techapp1.pdf). Although 21 (70%) of 
30 bacteremia episodes were preceded 
by phlebitis at a peripheral intravenous 
site, phlebitis caused by amphotericin 
was also common in patients without 
bacteremia (49%), but these percent-
ages did not differ statistically.
Accurate data regarding inci-
dence of nosocomial infections in Af-
rica are lacking. A systematic review 
by WHO in 2011 that assessed pub-
lished data for 1995–2009 identified 
only 2 high-quality studies. WHO 
estimated a prevalence of 2.5%–
14.8% for nosocomial infections 
and a cumulative incidence of up to 
45.8% in some areas (4) and recom-
mended surveillance to estimate the 
rates of nosocomial infection. WHO 
acknowledges that health care–asso-
ciated infections are causes of pro-
longed hospitalizations, increased an-
timicrobial drug resistance, financial 
burdens on health care systems, and 
causes of excess illness and death (5).
Limitations of our study include 
the retrospective design and inability 
to identify predictive risk factors for 
bacteremia. Given the differences in 
bacteremia incidence between our 2 
sites, findings are probably not gener-
alizable to all clinical settings in Af-
rica. However, these findings identify 
a clinical problem.
The incidence of nosocomial bacte-
remia was 15% in our hospitalized cryp-
tococcal meningitis cohort at a median 
time of 14 days after hospitalization. 
The most frequent etiologies were S. au-
reus and K. pneumonia. Less than 25% 
of isolates were sensitive to ceftriaxone, 
a standard empiric drug used throughout 
Africa. Further prospective studies are 
needed to determine the prevalence and 
risk factors for nosocomial infections 
and prevalence of multidrug resistance 
among hospitalized persons in resource- 
limited areas.
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Severe Babesiosis in 
Immunocompetent 
Man, Spain, 2011
To the Editor: Babesiosis, a 
malaria-like illness, is transmitted 
through Ixodes ticks by the zoonotic 
parasites, Babesia spp. In humans, 
these parasites are transferred from 
mammalian animal reservoirs, and 
the rate of infection in humans is in-
creasing. Babesiosis also potentially 
threatens the blood supply because 
asymptomatic infections in humans 
are common; such infections can be 
life-threatening in some recipients (1). 
Most human infection is caused by B. 
microti, but babesiosis caused by B. 
divergens, B. duncani, and B. venato-
rum has been reported.
Human babesiosis can be clini-
cally silent or progress to a fulminant 
malaria-like disease. The infection 
resolves spontaneously or after treat-
ment with azithromycin/atovaquone 
or clindamycin/quinine. However, 
immunocompromised patients may 
respond suboptimally to these drug 
regimens (2). Given the death rate 
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